The increasing burden of asthma in South African children: A call to action

R Masekela,1 PhD; C L Gray,2 PhD; R J Green,3 PhD, DSc; A I Manjra,4 FCPaed (SA), M Clin Pharm; F E Kritzinger,5 Cert Pulmonology (SA) Paed; M Levin,2 PhD; H Zar,2 PhD; on behalf of the South African Childhood Asthma Working Group

1 Inkosi Albert Luthuli Central Hospital and Department of Paediatrics and Child Health, School of Clinical Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
2 Department of Paediatrics and Adolescent Health, Red Cross War Memorial Children’s Hospital and Faculty of Health Sciences, University of Cape Town, South Africa
3 Steve Biko Academic Hospital and Department of Paediatrics and Child Health, School of Medicine, Faculty of Health Sciences, University of Pretoria, South Africa
4 Private Practice, Life Westville Hospital, Durban, South Africa
5 Netcare Christiaan Barnard Memorial Hospital, Cape Town; and Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

**Corresponding author:** R Masekela (masekelar@ukzn.ac.za)

**Background.** Asthma is a heterogeneous condition characterised by chronic inflammation and variable expiratory airflow limitation, as well as airway reversibility. The burden of asthma in children is increasing in low- and middle-income countries and remains under-recognised and poorly managed.

**Objectives.** To quantify the burden of asthma in the South African (SA) population and identify the risk factors associated with disease severity in the local context.

**Methods.** The SA Childhood Asthma Working Group (SACAWG) convened in January 2017 with task groups, each headed by a section leader, constituting the editorial committee on assessment of asthma epidemiology, diagnosis, control, treatments, novel treatments and self-management plans. The epidemiology task group reviewed the available scientific literature and assigned evidence according to the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) system.

**Conclusions.** Asthma in children remains a common condition, which has shown an increasing prevalence in urban and rural populations of SA. Of concern is that almost half of children in urban communities experience severe asthma symptoms, and many asthmatics lack a formal diagnosis and thus access to treatment. Exposure to tobacco smoke and living in highly polluted areas increase the severity of wheezing in young children.

Asthma is a heterogeneous condition characterised by chronic inflammation and variable expiratory airflow limitation, as well as airway reversibility. Worldwide, asthma is the most common chronic non-communicable disease in children. The most recent global estimate of asthma in adults and children (2008 - 2010) suggests that as many as 334 million people have asthma. The historical view of asthma being a disease of high-income countries no longer holds. Most people affected reside in low- and middle-income countries, where asthma prevalence is estimated to be increasing fastest, while plateauing in high-income countries. Asthma carries a high economic cost to society and the healthcare system, with costs being both direct (hospitalisation, medications and outpatient visits) and indirect (related to absenteeism and loss of productivity). Improving access to care and medications, coupled with use of and adherence to evidence-based treatments, can reduce the economic burden of asthma.

Accurate diagnosis of childhood asthma may be especially challenging in African settings, where respiratory infectious diseases predominate. In non-English-speaking populations, asthma terminology may not be easily translated into local languages. In resource-constrained areas, poor access to healthcare and lack of availability of lung function testing to confirm the diagnosis also contribute to delayed diagnosis. Questionnaire-based studies must be interpreted with caution, as these often rely on literate populations who understand the meaning of words such as ‘wheezing’ and ‘asthma’; this group of individuals may be prone to recall bias. Despite these limitations, the International Study of Asthma and Allergies in Childhood (ISACCA) has provided the most reliable global, comparative data on the prevalence of asthma and other allergic conditions in children, using standard written and video questionnaires, enabling comparison of asthma prevalence between different parts of the world.

**Objectives**

We reviewed the current literature on the burden of asthma in South Africa (SA) in the context of other low- and middle-income countries and on rural and urban differences in prevalence and severity of asthma.

**Methods**

The SA Childhood Asthma Working Group (SACAWG) convened in January 2017 with six task groups, each headed by a leader (Appendix A), constituting the editorial committee on assessment of asthma epidemiology, diagnosis, control, treatments, novel treatments and self-management plans. The task groups reviewed the available scientific literature on the burden of asthma from high-quality datasets and any local data on asthma prevalence and severity in
children, and graded the level of evidence and recommendations based on the current evidence.

**Asthma prevalence**

**Worldwide asthma prevalence**

ISAAC phase I and phase III studies, using identical questionnaires, were performed –7 years apart and enabled the investigation of time trends with regard to the symptoms of asthma. Studies were carried out in two age groups: children aged 6 - 7 years and adolescents aged 13 - 14 years. There was a significant variation in the prevalence of asthma between countries (Table 1). The prevalence of asthma in 13 - 14-year-old black African children was 15.3%, which was higher than the global average. Moreover, the prevalence of childhood asthma in African countries is increasing, compared with that in many high-income settings, where it has stabilised or is decreasing. Only two African centres in addition to SA centres included the younger age group of 6 - 7-year-olds. In these centres in Nigeria and Mozambique, the 12-month prevalence of wheeze was 5.6% and 13.3%, respectively. Overall, in Africa, the 12-month prevalence of wheeze was 10.0% in the 6 - 7-years age group. Globally, the current prevalence of wheeze in this age group is 11.5% and that of severe wheeze 4.9%.

The high, increasing prevalence of childhood asthma in Africa reported by ISAAC has been supported by studies measuring bronchial hyper-responsiveness (BHR) for diagnosing asthma. Such studies have shown a consistent increase in asthma prevalence in rural and urban settings in African countries. Furthermore, black African children with asthma have been reported to have more severe symptoms than those in high-income countries, which may relate to factors such as lack of diagnosis, access to care, affordability of therapy, as well as environmental irritants and genetic susceptibility to more severe disease, or a combination of these.

**Asthma prevalence in South Africa**

The prevalence of asthma in SA children was measured using the ISAAC methodology in Cape Town in 1995 (phase I) and repeated 7 years later in 2002 (phase III). Children aged 13 - 14 years, from all population groups, were included in the study. In 1995, a total of 5 178 children completed the questionnaire and in 2002, 5 037 children responded.

The prevalence of lifetime and 12-month wheezing increased between phase I and phase III from 27.7% to 33.1% and 16.0% to 20.3%, respectively (Table 2). Similarly, the 12-month prevalence of night waking with wheeze, severe wheeze, exercise-induced wheeze and nocturnal cough all increased significantly from 1995 to 2002. Worryingly, approximately half of all children with asthma had severe, uncontrolled symptoms. ISAAC phase III was conducted in a rural population in Polokwane, Limpopo, in 4 660 children aged 13 - 14 years. The 12-month prevalence of asthma was 18%, while the prevalence of severe asthma symptoms in Cape Town was less (6.6%). Using the ISAAC phase III methodology in a younger cohort (N = 2 437) of 6 - 7-year-old black African children in Polokwane, the 12-month prevalence of wheeze and severe wheeze was 11.2% and 5.7%, respectively. In this cohort, various potential risk factors and asthma symptoms were investigated. Living in a rural area was protective, which significantly decreased the likelihood of wheeze by 31%. Risk factors for the increased likelihood of wheeze included: exposure to environmental tobacco smoke (77%), eczema (104%) and rhinoconjunctivitis (226%) symptoms. The presence of rhinoconjunctivitis increased the likelihood of severe wheeze by 107%.

Studies in SA children measuring BHR confirmed the increase in asthma prevalence. In 1979, the first study of asthma prevalence in SA

---

**Table 1. Current prevalence of asthma symptoms by world region in 6 - 7-year and 13 - 14-year age groups as measured in ISAAC phase III**

<table>
<thead>
<tr>
<th>Region</th>
<th>6 - 7 years</th>
<th>13 - 14 years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>n</td>
</tr>
<tr>
<td>Africa</td>
<td>5 865</td>
<td>589</td>
</tr>
<tr>
<td>Asia-Pacific</td>
<td>59 979</td>
<td>5 719</td>
</tr>
<tr>
<td>Eastern Mediterranean</td>
<td>40 573</td>
<td>3 824</td>
</tr>
<tr>
<td>Indian subcontinent</td>
<td>50 092</td>
<td>3 392</td>
</tr>
<tr>
<td>Latin America</td>
<td>93 774</td>
<td>16 256</td>
</tr>
<tr>
<td>North America</td>
<td>4 012</td>
<td>767</td>
</tr>
<tr>
<td>Northern and Eastern Europe</td>
<td>42 548</td>
<td>3 715</td>
</tr>
<tr>
<td>Oceania</td>
<td>13 888</td>
<td>3 020</td>
</tr>
<tr>
<td>Western Europe</td>
<td>77 722</td>
<td>7 487</td>
</tr>
<tr>
<td>Global total</td>
<td>388 811</td>
<td>44 799</td>
</tr>
</tbody>
</table>

ISAAC = International Study of Asthma and Allergies in Childhood; n = number of participants with a positive asthma-screening questionnaire.

---

**Table 2. Current prevalence of asthma symptoms (12-month prevalence rate of wheeze) by region in South Africa in 6 - 7-year and 13 - 14-year age groups as measured in ISAAC phase I and phase III**

<table>
<thead>
<tr>
<th>Region</th>
<th>6 - 7 years</th>
<th>13 - 14 years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>Cape Town (ISAAC I)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cape Town (ISAAC III)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Polokwane (ISAAC III)</td>
<td>2 437</td>
<td>11.2</td>
</tr>
</tbody>
</table>

ISAAC = International Study of Asthma and Allergies in Childhood.
children found a 30-fold higher prevalence in urban (3.1%) compared with rural (0.01%) Xhosa children aged 7 - 9 years. A follow-up study in 2003 reported an increase in asthma prevalence in urban and rural children, with a reduction in the urban-rural gradient. Increased BHR was associated with rural children adopting an urban lifestyle. A later study measuring BHR also confirmed an increase in asthma prevalence in urban (15%) and rural (9%) Xhosa children, with a reduction in the urban-rural gradient. Obesity was identified as a risk factor for an increase in BHR. The most recent study showed BHR in 16% of peri-urban black African teenagers, with high rates of allergen sensitisation in individuals with BHR.

Risk factors for asthma

Ecema is an important risk factor for asthma, and longitudinal studies have shown that from one-third to one-half of children with ecema develop asthma. In a SA study of 100 children with atop dermatitis, 39% described symptoms of asthma according to the ISAAC questionnaire, and in 29% asthma was diagnosed by a doctor. Asthma prevalence increased with age; at the time of the study asthma symptoms were present in 22% of children <2 years old, 43% of 2 - 4-year-olds and 50% of children >4 years old. Industrial pollution is a further risk factor associated with a higher prevalence of asthma. A study in Durban questioned 422 learners (average age 10.5 years) on symptoms of asthma. In this cohort, the presence of symptoms that were consistent with asthma of any severity was 32%, and the prevalence of doctor-diagnosed asthma was 13.0 - 16.5%, depending on the area surveyed. Children from areas with higher levels of industrial pollution had a higher prevalence of respiratory health problems. In a separate study in a highly polluted area in the south of Durban, which included 248 school-aged participants from grades 3 to 7, 52% had asthma of any severity, 11% had moderate-to-severe persistent asthma, and 21% had marked airways hyperreactivity on methacholine challenge testing.

Asthma morbidity and mortality

Almost half of children in Cape Town who reported asthma in ISAAC phase III had severe symptoms. Furthermore, >30% of children with severe asthma symptoms had never been formally diagnosed with asthma. In addition to morbidity from childhood asthma, SA has a very high rate of asthma-related deaths, suggesting that lack of appropriate diagnosis, treatment or access to care may be important considerations. Although SA was ranked 25th worldwide for the prevalence of asthma, it ranked 4th in asthma mortality in the 5 - 34-year-old age group and 5th for asthma case fatality rates, with an estimated 18.5 per 100 000 asthmatics.

Conclusion

Childhood asthma remains a common condition, which has shown an increasing prevalence in urban and rural populations in SA. Of concern is that almost half of children in urban communities experience severe asthma symptoms, and many asthmatics lack a formal diagnosis and thus access to treatment. Exposure to tobacco smoke and living in highly polluted areas increase the severity of wheezing in young children.

Acknowledgements

We acknowledge the hard work and contribution of the South African Childhood Asthma Working Group (SACAWG) members. We also acknowledge the huge contribution of the late Prof. Cas Motala, who was convener of the past three SACAWG guidelines.

Author contributions

RM: review, write-up and manuscript editing; HZ, CLG: conceptualisation, methodology, write-up and manuscript editing; and ML, RJG, AIM, FEK: write-up and manuscript editing.

Funding

SACAWG conducted a workshop that received an unconditional educational grant from the Allergy Society of South Africa – funded by Novartis.

Conflicts of interest.

None.


Accepted 7 May 2018.